Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 11, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 31, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 10, 2026Reported sale · Form 4Mary C Beckerle · $526.5KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,20614 flagged findings
Reported transactions (Form 4)80since May 21, 2024 · and 3 other holdings
Corporate events (8-K)30since Jul 20, 2017
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Identity
Formerly traded as EXL1V.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-05capital return (buybacks/dividends)recentOpen filing ↗“…31, 2026. In May 2026, our Board of Directors authorized the repurchase of up to an additional $ 750.0 million of our outstanding…”
+1 more passage from the same document
- “…May 2026. In May 2026, our Board of Directors authorized the repurchase of up to an additional $750.0 million of our outstanding…”
- 2026-05-05capital return (buybacks/dividends)recentOpen filing ↗“…of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference…”
+1 more passage from the same document
- “…shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis,…”
- 2026-02-10capital return (buybacks/dividends)recentOpen filing ↗“…paid dividends on our common stock. We currently do not plan to pay any cash dividends in the foreseeable future. Any future…”
+1 more passage from the same document
- “…dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.…”
- 2026-02-10regulatory investigationrecentOpen filing ↗“…integrity agreements that impose significant reporting and other requirements. Should we or our hub providers receive a…”
- 2026-02-10Department of Justice inquiryrecentOpen filing ↗“…our hub activities are also subject to scrutiny and may create risk for us if not conducted in accordance with the views of…”
+1 more passage from the same document
- “…Congress passed H.B. 815, which included the Protecting Americans’ Data from Foreign Adversaries Act of 2024, creating restrictions…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 2,206)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 11, 268-K ↗Current report · Other events
- Aug 31, 268-K ↗Current report · Other events
- Aug 14, 26SCHEDULE 13D/A ↗Stake with intent to influence · Farallon Capital Management, L.L.C. · 5.6% · amendment
- Aug 12, 26SCHEDULE 13G/A ↗Passive stake · AQR Capital Management, LLC · 4.4% · event on Jun 30, 26 · amendment
- Aug 12, 26Form 4 ↗Insider transaction
- Aug 10, 26Form 144 ↗Notice of proposed sale
- Aug 5, 2610-Q ↗Quarterly report
- Aug 5, 268-K ↗Current report · Results
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Jun 1, 26Form 144 ↗Notice of proposed sale
- Jun 1, 26Form 144 ↗Notice of proposed sale
Insider transaction · 9 Form 4 filingsshow all 9hide
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 26Form 4 ↗Insider transaction
- May 29, 268-K ↗Current report · A senior executive left or was appointed
- May 26, 26Form 144 ↗Notice of proposed sale
2,206 filings on record, the oldest from Apr 24, 00.
Listing the 25 most recent filings of the 2,206 on record.
88664
6 senior executive changes2024 – 2026show all 6hide
- May 29, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Nov 7, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Aug 29, 25A senior executive left or was appointed8-K 5.02 ↗
- Mar 31, 25A senior executive left or was appointed8-K 5.02 ↗
- Jun 3, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 29, 24A senior executive left or was appointed8-K 5.02 ↗
- Jan 8, 24Restructuring plan with committed costs+4 more in the same filing8-K 2.05 ↗
14 senior executive changes2020 – 2023show all 14hide
- Dec 20, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 19, 23A senior executive left or was appointed8-K 5.02 ↗
- Aug 23, 23A senior executive left or was appointed8-K 5.02 ↗
- May 8, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 13, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 15, 22A senior executive left or was appointed8-K 5.02 ↗
- May 27, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 13, 22A senior executive left or was appointed8-K 5.02 ↗
- Dec 17, 21A senior executive left or was appointed8-K 5.02 ↗
- Jun 21, 21A senior executive left or was appointed8-K 5.02 ↗
- Mar 5, 21A senior executive left or was appointed8-K 5.02 ↗
- Feb 5, 21A senior executive left or was appointed8-K 5.02 ↗
- May 22, 20A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 2, 20A senior executive left or was appointed8-K 5.02 ↗
- Dec 19, 19Entered a material agreement8-K 1.01 ↗
- Apr 5, 19Entered a material agreement+2 more in the same filing8-K 1.01 ↗
4 senior executive changes2017 – 2019show all 4hide
- Mar 5, 19A senior executive left or was appointed8-K 5.02 ↗
- Apr 9, 18A senior executive left or was appointed8-K 5.02 ↗
- Feb 16, 18A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 8, 17A senior executive left or was appointed8-K 5.02 ↗
- Jul 20, 17Entered a material agreement8-K 1.01 ↗
The record reaches back to Sep 16, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Apr 30, 15Restructuring plan with committed costs8-K/A 2.05 ↗
- Sep 5, 14Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Feb 22, 11Restructuring plan with committed costs8-K/A 2.05 ↗
- Dec 7, 10Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
- May 5, 10Restructuring plan with committed costs8-K/A 2.05 ↗
- Mar 8, 10Restructuring plan with committed costs8-K 2.05 ↗
- Nov 7, 08Restructuring plan with committed costs8-K 2.05 ↗
The full record holds 8 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Dapice Joshua J.5.9%Jan 1, 26SCHEDULE 13D/A ↗31 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Farallon Capital Management, L.L.C.5.6%Aug 14, 26SCHEDULE 13D/A ↗29 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.10.2%Mar 31, 25SCHEDULE 13G/A ↗
- Vanguard Capital Management5.1%Mar 31, 26SCHEDULE 13G ↗
- AQR Capital Management, LLC4.4%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 10, MARY BECKERLE filed notice of intent to sell up to $526K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $527K on Aug 10, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
- Aug 10, 26Sell$527KMary C Beckerle↗
- Jun 1, 26Sell$492KSue Gail Eckhardt↗
- Jun 1, 26Sell$198KJACK L WYSZOMIERSKI↗
- May 26, 26Sell$2.2MDana AftabEVP, Research and Development↗
- May 20, 26Sell$1.6MPatrick J. HaleyEVP, Commercial↗
- May 18, 26Sell$333KBrenda HeftiSVP and General Counsel↗
- May 18, 26Sell$1.7MChristopher J. SennerEVP and CFO↗
- May 7, 26Sell$2.7MGEORGE POSTE↗
- May 7, 26Sell$949KMaria C Freire↗
- May 7, 26Sell$374KMary C Beckerle↗
- Feb 24, 26Sell$2.1MDana AftabEVP, Research and Development↗
- Feb 19, 26Sell$1.3MDana AftabEVP, Research and Development↗
There are 2 more transactions in this stretch.
Stock compensation, tax and giftsshow the 26 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- May 27, 26Compensationamount n/aGEORGE POSTE↗
- May 27, 26Compensationamount n/aJACK L WYSZOMIERSKI↗
- May 27, 26Compensationamount n/aBob Oliver↗
- May 27, 26Compensationamount n/aMary C Beckerle↗
- May 27, 26Compensationamount n/aMaria C Freire↗
- May 27, 26Compensationamount n/aJulie Smith↗
- May 27, 26Compensationamount n/aSue Gail Eckhardt↗
- May 27, 26Compensationamount n/aTomas J. Heyman↗
- May 27, 26Compensationamount n/aSTELIOS PAPADOPOULOS↗
- May 18, 26Giftamount n/aMICHAEL MORRISSEYPresident and CEO↗
- May 15, 26Tax$1.6MDana AftabEVP, Research and Development↗
- May 15, 26Tax$328KBrenda HeftiSVP and General Counsel↗
- May 15, 26Tax$1.7MPatrick J. HaleyEVP, Commercial↗
- May 15, 26Tax$2.1MChristopher J. SennerEVP and CFO↗
- May 15, 26Tax$6.6MMICHAEL MORRISSEYPresident and CEO↗
- May 7, 26Compensation$408KMaria C Freire↗
- May 7, 26Compensation$90KMary C Beckerle↗
- May 6, 26Giftamount n/aMICHAEL MORRISSEYPresident and CEO↗
- Feb 26, 26Compensationamount n/aMICHAEL MORRISSEYPresident and CEO↗
- Feb 26, 26Compensationamount n/aPatrick J. HaleyEVP, Commercial↗
- Feb 26, 26Compensationamount n/aBrenda HeftiSVP and General Counsel↗
- Feb 26, 26Compensationamount n/aChristopher J. SennerEVP and CFO↗
- Feb 26, 26Compensationamount n/aDana AftabEVP, Research and Development↗
- Feb 24, 26Giftamount n/aMICHAEL MORRISSEYPresident and CEO↗
- Feb 18, 26Compensation$855KJulie Smith↗
- Feb 18, 26Compensation$434KJulie Smith↗
The full record holds 378 transactions and goes back to Dec 7, 22.
Its sector and its market
Exelixis Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Exelixis Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Exelixis Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,206 documents on file, from Apr 24, 2000 to Sep 11, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.